Plato Investment Management Ltd Takes Position in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Plato Investment Management Ltd bought a new position in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA - Free Report) during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 63,530 shares of the company's stock, valued at approximately $1,144,000.

A number of other hedge funds and other institutional investors also recently modified their holdings of the company. New Covenant Trust Company N.A. bought a new position in Teva Pharmaceutical Industries during the 1st quarter worth $28,000. EntryPoint Capital LLC purchased a new position in Teva Pharmaceutical Industries during the first quarter worth about $30,000. UMB Bank n.a. increased its position in shares of Teva Pharmaceutical Industries by 555.6% during the 3rd quarter. UMB Bank n.a. now owns 2,439 shares of the company's stock valued at $44,000 after purchasing an additional 2,067 shares during the last quarter. Beach Investment Counsel Inc. PA purchased a new position in Teva Pharmaceutical Industries in the second quarter valued at about $48,000. Finally, Byrne Asset Management LLC purchased a new stake in shares of Teva Pharmaceutical Industries during the 2nd quarter worth approximately $52,000. Institutional investors and hedge funds own 54.05% of the company's stock.

Teva Pharmaceutical Industries Trading Down 1.9 %

Shares of NYSE:TEVA traded down $0.32 during trading on Friday, reaching $16.44. 8,734,078 shares of the company were exchanged, compared to its average volume of 9,253,895. Teva Pharmaceutical Industries Limited has a 12-month low of $8.64 and a 12-month high of $19.31. The company has a debt-to-equity ratio of 2.57, a current ratio of 0.89 and a quick ratio of 0.61. The business's fifty day simple moving average is $17.81 and its 200-day simple moving average is $17.20. The firm has a market capitalization of $18.62 billion, a PE ratio of -19.33, a P/E/G ratio of 1.32 and a beta of 0.87.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on TEVA shares. UBS Group lifted their price objective on shares of Teva Pharmaceutical Industries from $24.00 to $26.00 and gave the stock a "buy" rating in a report on Tuesday, September 3rd. JPMorgan Chase & Co. increased their price objective on Teva Pharmaceutical Industries from $16.00 to $18.00 and gave the company a "neutral" rating in a research report on Monday, October 21st. StockNews.com upgraded shares of Teva Pharmaceutical Industries from a "buy" rating to a "strong-buy" rating in a research note on Thursday, October 17th. Finally, Barclays increased their price objective on shares of Teva Pharmaceutical Industries from $22.00 to $25.00 and gave the company an "overweight" rating in a report on Wednesday, October 23rd. Two investment analysts have rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average price target of $19.67.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.